Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis.


Journal

CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244

Informations de publication

Date de publication:
02 2020
Historique:
received: 16 04 2019
accepted: 09 10 2019
pubmed: 28 10 2019
medline: 17 6 2021
entrez: 27 10 2019
Statut: ppublish

Résumé

Secukinumab is effective to treat plaque psoriasis. However, the safety and efficiency of secukinumab have not been clarified in patients on hemodialysis. We report a 60-year-old Japanese woman. Plaque psoriasis was diagnosed at the age of 25 years and hemodialysis was started at the age of 39 years. Her skin lesions persisted despite use of topical agents such as maxacalcitol and betamethasone. Accordingly, administration of secukinumab was started at a dose of 150 mg. The psoriasis area and severity index (PASI) score decreased from 49.8 to 14.8 after 2 weeks and to 0 after 6 weeks, with remission being maintained after 28 months. No adverse reactions were seen. This case indicates that secukinumab may be effective for severe psoriasis in patients on hemodialysis for end-stage renal disease.

Identifiants

pubmed: 31654299
doi: 10.1007/s13730-019-00426-z
pii: 10.1007/s13730-019-00426-z
pmc: PMC6990267
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
secukinumab DLG4EML025

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

55-58

Références

J Dermatol. 2014 Dec;41(12):1039-46
pubmed: 25354738
Curr Opin Rheumatol. 2015 Mar;27(2):127-33
pubmed: 25599143
Drug Discov Today. 2006 Jan;11(1-2):81-8
pubmed: 16478695
Dermatologica. 1978;157(4):238-44
pubmed: 357213
J Dermatol. 2012 Mar;39(3):242-52
pubmed: 21955098
Arthritis Care Res (Hoboken). 2013 Mar;65(3):471-5
pubmed: 22807318
Ther Clin Risk Manag. 2015 Dec 02;11:1767-77
pubmed: 26664127
J Pharm Pharmacol. 2005 Nov;57(11):1407-13
pubmed: 16259772
Am J Kidney Dis. 2002 Mar;39(3):571-9
pubmed: 11877576
J Dermatol Sci. 2010 Jul;59(1):40-9
pubmed: 20547039
Int J Dermatol. 2008 Sep;47(9):980-1
pubmed: 18937672
J Dermatol. 2015 Jul;42(7):731-4
pubmed: 25959602
Clin Rheumatol. 2010 Dec;29(12):1455-9
pubmed: 20490588
J Dermatol. 2010 Apr;37(4):299-310
pubmed: 20507398
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90
pubmed: 25243910
J Dermatol. 2015 Jul;42(7):727-30
pubmed: 25916786

Auteurs

Daiuske Ikuma (D)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan. gdikuma@gmail.com.

Masahiko Oguro (M)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Junichi Hoshino (J)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Hiroki Mizuno (H)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Akinari Sekine (A)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Masahiro Kawada (M)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Rikako Hiramatsu (R)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Keiichi Sumida (K)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Eiko Hasegawa (E)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Noriko Hayami (N)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Masayuki Yamanouchi (M)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Tatsuya Suwabe (T)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Naoki Sawa (N)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Kenmei Takaichi (K)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Yoshifumi Ubara (Y)

Nephrology Center, Toranomon Hospital, 2-2-2Minato-ku, ToranomonTokyo, 105-0001, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH